Akebia Ther - Asset Resilience Ratio
Akebia Ther (AKBA) has an Asset Resilience Ratio of 38.11% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AKBA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2021)
This chart shows how Akebia Ther's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Akebia Ther to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Akebia Ther's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AKBA stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $83.92 Million | 38.11% |
| Total Liquid Assets | $83.92 Million | 38.11% |
Asset Resilience Insights
- Very High Liquidity: Akebia Ther maintains exceptional liquid asset reserves at 38.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Akebia Ther Industry Peers by Asset Resilience Ratio
Compare Akebia Ther's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Akebia Ther (2013–2021)
The table below shows the annual Asset Resilience Ratio data for Akebia Ther.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $529.35 Million | -- |
| 2020-12-31 | 6.21% | $39.99 Million | $644.14 Million | +6.18pp |
| 2019-12-31 | 0.03% | $245.00K | $771.20 Million | -21.74pp |
| 2018-12-31 | 21.77% | $217.00 Million | $996.54 Million | -46.21pp |
| 2017-12-31 | 67.99% | $247.64 Million | $364.25 Million | +43.67pp |
| 2016-12-31 | 24.32% | $73.01 Million | $300.22 Million | -37.72pp |
| 2015-12-31 | 62.04% | $88.68 Million | $142.94 Million | -6.56pp |
| 2014-12-31 | 68.60% | $76.14 Million | $111.00 Million | +35.88pp |
| 2013-12-31 | 32.72% | $11.34 Million | $34.66 Million | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more